[go: up one dir, main page]

MX2014011849A - Reactivos, procedimientos y kits para la clasificación del cáncer. - Google Patents

Reactivos, procedimientos y kits para la clasificación del cáncer.

Info

Publication number
MX2014011849A
MX2014011849A MX2014011849A MX2014011849A MX2014011849A MX 2014011849 A MX2014011849 A MX 2014011849A MX 2014011849 A MX2014011849 A MX 2014011849A MX 2014011849 A MX2014011849 A MX 2014011849A MX 2014011849 A MX2014011849 A MX 2014011849A
Authority
MX
Mexico
Prior art keywords
cancer
antibody capable
specifically binding
tissue
binding
Prior art date
Application number
MX2014011849A
Other languages
English (en)
Inventor
Carl S Shelley
Qiangwei Fu
Steven E Cash
Jremiah J Andersen
Original Assignee
Gundersen Lutheran Health System Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gundersen Lutheran Health System Inc filed Critical Gundersen Lutheran Health System Inc
Publication of MX2014011849A publication Critical patent/MX2014011849A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/5752—
    • G01N33/5758—

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen reactivos, métodos y kits para la clasificación del cáncer que comprenden o emplean anticuerpos que se unen las regiones específicas de CD43. Un método incluye poner en contacto el tejido con un anticuerpo capaz de unirse específicamente a la cola citoplásmica de CD43; poner en contacto el tejido con un anticuerpo capaz de unirse específicamente al dominio extracelular de CD43, y resolver la localización celular de cualquier unión al tejido con el anticuerpo capaz de específicamente de unión a la cola citoplásmica de CD43 y el anticuerpo capaz de unirse específicamente al dominio extracelular de CD43. Los patrones de unión de los anticuerpos se pueden usar para caracterizar el cáncer como más agresivo o menos agresivo y puede distinguir el cáncer de pulmón de células no-pequeñas de cáncer de pulmón. Por tanto, el cáncer puede ser tratado de acuerdo con la caracterización.
MX2014011849A 2012-04-02 2013-04-02 Reactivos, procedimientos y kits para la clasificación del cáncer. MX2014011849A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261619002P 2012-04-02 2012-04-02
US201361790898P 2013-03-15 2013-03-15
PCT/US2013/034967 WO2013152010A1 (en) 2012-04-02 2013-04-02 Reagents, methods, and kits for the classification of cancer

Publications (1)

Publication Number Publication Date
MX2014011849A true MX2014011849A (es) 2015-04-08

Family

ID=48087774

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011849A MX2014011849A (es) 2012-04-02 2013-04-02 Reactivos, procedimientos y kits para la clasificación del cáncer.

Country Status (7)

Country Link
US (1) US8999657B2 (es)
EP (1) EP2834641A1 (es)
JP (1) JP2015514985A (es)
AU (1) AU2013243560A1 (es)
CA (1) CA2869394A1 (es)
MX (1) MX2014011849A (es)
WO (1) WO2013152010A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10032331B2 (en) * 2015-01-20 2018-07-24 Gamblit Gaming, Llc Color alteration interleaved wagering system
US10055936B2 (en) 2015-01-21 2018-08-21 Gamblit Gaming, Llc Cooperative disease outbreak interleaved wagering system
FR3056664B1 (fr) * 2016-09-23 2018-09-28 Renault S.A.S Procede de synchronisation d'un pignon fou sur un arbre de boite de vitesses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0339695A3 (en) 1988-04-29 1990-05-30 Stichting Voor De Technische Wetenschappen A process for preparing an antigenic or immunogenic conjugate as well as the use of such conjugates
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
WO2004026120A2 (en) 2002-09-23 2004-04-01 The General Hospital Coporation Methods for diagnosing and treating tumors and suppressing cd promoters
KR101510753B1 (ko) 2006-06-07 2015-04-10 바이오얼라이언스 씨.브이. 암세포 상에서 발현되는 ｃｄ-43 및 ｃｅａ 상의 에피토프를 함유하는 탄수화물을 인식하는 항체 및 이를 이용하는 방법

Also Published As

Publication number Publication date
JP2015514985A (ja) 2015-05-21
US20130259877A1 (en) 2013-10-03
EP2834641A1 (en) 2015-02-11
US8999657B2 (en) 2015-04-07
WO2013152010A1 (en) 2013-10-10
CA2869394A1 (en) 2013-10-10
AU2013243560A1 (en) 2014-10-23

Similar Documents

Publication Publication Date Title
GB2556004A (en) Markers of stroke and stroke severity
CY1124108T1 (el) Μορια συνδεσης που αναστελουν την αναπτυξη καρκινου
MX394474B (es) Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo.
MX2017009998A (es) Biomarcadores para cancer pancreatico.
UY32501A (es) Anticuerpo antagonista específico para el heterodímero alfa4-beta7
MX2015006680A (es) Composiciones y metodos para diagnosticar tumores de tiroides.
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
MX350533B (es) Biomarcadores de cancer pancreatico y usos de los mismos.
JOP20170041B1 (ar) اجسام مضادة ضد vista (b7h5)
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
BR112015001592A8 (pt) análise de imagem e medidas de amostras biológicas
BR112014019579A2 (pt) Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
CO6450618A2 (es) Anticuerpos especificos para cadherina-17
MX373248B (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
AR089825A1 (es) Metodo para determinar la ubicacion, tamaño y condiciones in situ en un yacimiento de hidrocarburos con ecologia, geoquimica y grupos de biomarcadores
MX387936B (es) Metodo para la cuantificacion de huevos de parasitos en las heces.
EA201692157A1 (ru) Синтез двухцепочечных нуклеиновых кислот
BR112014032916A2 (pt) anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
AU2013252445A8 (en) Assays, methods and apparatus for assessing RNA disruption
MX352373B (es) Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
MX2019008911A (es) Metodos, matrices y usos de estos.
EA201990730A1 (ru) Рнк-биомаркеры для наследственного ангионевротического отека
WO2015091575A3 (en) Different levels in blood cell samples of emt-markers for the diagnosis of cancer, in particular of colorectal (crc) and pancreatic (pc) cancer